ReactArray systems have been developed in collaboration with the pharmaceutical industry to facilitate high throughput reaction screening and optimisation.
MRSP will use its specialised knowledge of the pharmaceutical and speciality chemical markets to support ReactArray and its existing dealer network, accelerating awareness and market uptake of this product suite.
MRSP CEO, Dr. Thomas Schwalbe commented, "We are very pleased to work with ReactArray as it gives us the opportunity to provide best-in-class robotic batch technology to our existing customers."
"Recent extensions to the product suite enable drug stressing, solubility testing and chemical synthesis applications that will be particularly welcomed by chemists world wide."
"The new Solo product will boost the productivity of those process chemistry groups that have been waiting for a lower-cost entry into parallel synthesis workstations."
ReactArray Group Manager Mark Harding added, "Drs Thomas Schwalbe and Keith Simons (VP Business Development, MRSP) are both well known and highly regarded in the market place and we are delighted to be entering into this relationship."
"Greater awareness of ReactArray and new applications will help more scientists in both industry and research organisations understand its capabilities and benefit from the solutions it can provide them."